Pfizer's RSV acquisition target is Novo Ventures portfolio company
Reviral, which Pfizer intends to acquire in a deal that could total USD 525m, has received several investments from Novo Ventures.
Pfizer has entered into an acquisition agreement with London based Reviral, which develops antiviral treatments for respiratory syncytial virus (RSV), in a deal that could reach USD 525m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to acquire Reviral as RSV race continues
For subscribers
.jpg&w=384&q=75)
